Rita Nahta - Concepedia

Author

Rita Nahta

Emory University

Also Known As

R NAHTA, R Nahta, R. Nahta, Rita Nahta, Ward, Andrew

103

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Emory University The University of Texas MD Anderson Cancer Center Winship Cancer Institute Children's Healthcare of Atlanta The Ohio State University

About

Rita Nahta is an author at Emory University specializing in breast cancer, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	1.2K
2	Natural Sciences	3	3	164
3	Engineering	2	2	134
4	Biochemistry	2	2	148
5	Health Sciences	1	1	21

Rita Nahta

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells Rita Nahta, Linda X.H. Yuan, Bing Zhang, Cancer Research	2005	792
The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells Rita Nahta, Mien‐Chie Hung, Francisco J. Esteva Cancer Research	2004	599
P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells Rita Nahta, Takeshi Takahashi, Naoto T. Ueno, Cancer Research	2004	291
Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism Yuhua Zhao, Hao Liu, Zixing Liu, Cancer Research Trastuzumab ResistanceBreast OncologyOncologyGlycolysis InhibitorsAerobic Glycolysis	2011	285
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Rita Nahta, Linda X.H. Yuan, Yi Du, Molecular Cancer Therapeutics	2007	263
HER-2-targeted therapy: lessons learned and future directions. Rita Nahta, Francisco J. Esteva PubMed Breast OncologyImmunologyPathologyPharmacotherapyImmunotherapy	2003	179
Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma Francisco J. Esteva, Ayşegül A. Şahin, Terry L. Smith, Cancer	2004	127
FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells LaTonia Taliaferro‐Smith, Elaine M. Oberlick, Tongrui Liu, Oncotarget	2015	122
Catalytic Deoxyribozyme-Modified Nanoparticles for RNAi-Independent Gene Regulation Kevin Yehl, Jayashree Joshi, Brandon L. Greene, ACS Nano NanotherapeuticsEngineeringMetal NanoparticlesMolecular BiologyGene Delivery	2012	100
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Rita Nahta ISRN Oncology Resistance PathwaysDual Her2 InhibitionBreast OncologyTrastuzumab-based TreatmentImmunology	2012	89

Page 1